Bullpen.News · the best place to find stock ideas

Market Cracks Under AI Debt Burden | The Weekly Wrap

Steve Eisman examines AI data-center debt, CoreWeave's tech correction and agentic AI's effect on banks as earnings season begins.

CRWV $34BBAC $377B

Steve Eisman 25h ago 11 clicks

27h ago META $1.9T

OpenAI Does Math, Reward Hacking, Meta Launches Personal Agent

Stratechery by Ben Thompson – On the business, strategy, and impact of technology. 4 clicks

27h ago META $1.9T

One More Note on Agents, Meta Connect, Meta Enterprise Platform

Stratechery by Ben Thompson – On the business, strategy, and impact of technology. 8 clicks

From X

@ACapitalLP 51m ago 1 click

A Capital on X

The asset base is too large and diversified to ever underwrite loan by loan. The thesis is that the private credit apocalypse is exaggerated, $OWL became the poster child given its reliance on the HNW channel, and the market is assigning far too little value to its non-credit assets and durable fee-generating franchise.

@gnoble79 3h ago 3 clicks

George Noble on X

@FrenchV33921 Already there with $CRWV and $IREN IS $NBIS worse?

@calvinblissett 4h ago

Calvin Blissett on X

@sidecarcap This is exactly what I think is happening with $SLM $KSPI and maybe $YB. $KNSL too

@ACapitalLP 4h ago 1 click

A Capital on X

@Pembrokestcap But isn’t $OWL reputation, and by extension their ability to raise capital, permanently impaired? Who cares if they own valuable GP stakes and real estate businesses that never tapped the high-net-worth channel? Isn’t the entire franchise structurally compromised?

@finphysnerd 4h ago

Myles on X

Shorts that aren't actually that overvalued (a 10+15% grower trading at 30x earnings can be overvalued, but still easily trade to 40-50x). Sizing is very important. Stuff like $CBA, $WDFC, $WMT, $WING have been some of my biggest winners this year with no catalyst.

@ACapitalLP 5h ago

A Capital on X

My favorite part of this $OWL article… What possible value could investment bankers see in a full or partial sale of the business that the public market is apparently missing? https://t.co/5rjY1IZQv1 https://t.co/yWPrLNBD21

@leevalueroach 6h ago

Lee Roach on X

Wall Street finally started to see the GameStop $GME transformation. Dan Ives just made a comment on the company. Wait until other sheep start piling into the story. https://t.co/PsHMLM94Tv

@convequity 8h ago

Convequity on X

We think the gross margin gap between Cerebras ($CBRS) and NVIDIA ($NVDA) says little about which company delivers compute more cheaply. Cerebras reported a 14% gross margin in Q2 2026, against roughly 75% for NVIDIA. That is not a clean comparison, because Cerebras's commercial agreements include customer warrants. A customer warrant gives a buyer of Cerebras compute the right to buy Cerebras shares at an agreed price, adding potential equity upside to the compute it purchases. Cerebras records the value of these incentives over time as a reduction in revenue. Its cost of delivering the compute stays the same, so the full amount comes out of gross profit and its reported gross margin falls too. Add the warrants and a few other items back and Cerebras's Q2 margin was 41%, so the reported gap tells us little about what each company spends to deliver equivalent compute. Cerebras could challenge NVIDIA with attractive economics on selected workloads without matching every capability of NVIDIA's platform. In our view NVIDIA's stronger answer is Feynman reaching customers on schedule with the 3D-stacked SRAM we expect. Stacking more fast memory close to the compute would reduce the need to fetch data from slower external memory, helping NVIDIA narrow the architectural advantage behind Cerebras's fast inference. NVIDIA's adoption of Groq technology could ease some of this pressure, but we believe Groq's current architecture remains weaker than Cerebras's for low-latency inference. The longer Feynman takes to arrive at scale, the more time Cerebras has to win customers.

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

2026.42: Home At Last

Stratechery’s weekly bundle covers Apple HomeView and SpaceX’s cellular ambitions.

AAPL $5T

Stratechery by Ben Thompson – On the business, strategy, and impact of technology. 27h ago 2 clicks

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

NFLX $511B

TSOH Investment Research 30h ago 6 clicks

GE Vernova: AI's Next Bottleneck Is Electricity

GE Vernova’s 116 GW gas-turbine backlog and $5 billion in early-2026 data-center orders target AI-driven electricity demand, though its…

GEV $251B

Todd Feldman 41h ago 2 clicks

Is The Market Turning The Page?

CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.

CRWV $34B

WHAT ARE WE DOING? “Contrarians At The Gate” Oct 15 51 clicks

ASML Is Building a Hybrid Bonding Tool!

ASML’s patent filings point to a track-based die-to-wafer hybrid bonding tool that could challenge Besi in advanced logic packaging.

ASML $631B

SemiAnalysis Oct 15 11 clicks

CoreWeave: Why Credit Markets See A 54% Chance Of Default

CoreWeave’s 2032 notes yield over 15%, signaling a 54% default probability as borrowing costs exceed rental yields on AI infrastructure…

CRWV $34B

Dustin Quasney Oct 15 21 clicks

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…

APP $88B

Speedwell Research Oct 15 24 clicks

ASML 3Q’26: 2030 Arrived Four Years Early

ASML reported €11.7 billion in 3Q 2026 sales, up 55%, and raised full-year guidance to €44–45 billion as AI-driven semiconductor demand…

ASML $631B

MBI Deep Dives Oct 15 11 clicks

Berkshire B: Holding, Developing Headwinds Have Yet To Reflect In Stock Price, In My View

Berkshire Hathaway trades at 1.46 times book as reinsurance pricing pressure, softer P&C, concentrated equities and cash weigh on its…

BRK.A $1.1T

Pearl Gray Equity and Research Oct 15 3 clicks

[scuttleslops] MRVL, APP, AMZN, Chips

Marvell is positioning networking, optical connectivity and server-management chips as AI data centers link GPUs, custom accelerators and…

MRVL $208B

scuttleblurb Oct 15 12 clicks

Berkshire Hathaway’s 2024 Annual Report

Berkshire Hathaway ended 2024 with $318 billion of adjusted cash and $47.4 billion of operating earnings, led by insurance underwriting and…

BRK.A $1.1T

The Rational Walk Feb 26

Berkshire Hathaway’s Culture in 2050

Berkshire Hathaway’s post-Buffett culture will depend on Greg Abel and a shrinking family foundation’s voting control as Class A shares…

BRK.A $1.1T

The Rational Walk Feb 21

Staying the Course

Berkshire Hathaway ownership, rather than broad index funds, kept the investor committed through volatility, backed by trust in Buffett’s…

BRK.A $1.1T

The Rational Walk Feb 14

Some Thoughts on Roaring Kitty

Roaring Kitty’s GameStop resurgence revisits GME shareholder activism and the meme-stock trading episode, with references to Bed Bath &…

GME $14B

Rod’s Ruminations May 21

(C)riminally (V)alued (S)caled Healthcare Services

CVS Health fell 20% after cutting 2024 adjusted EPS guidance to $7, but its Aetna insurance and Caremark PBM businesses support a…

CVS $118B

Rod’s Ruminations May 1

Summary of Q4 Restaurant Conference Calls

Restaurant operators reported improving traffic, accelerating unit growth and higher advertising spend, while wage inflation ran 4-5% and…

MCD $173B

Investing 501 Mar 14

Highlights from Darden Restaurants' Q2 '23 Conference Call

Darden Restaurants posted 2.8% same-store sales growth as Olive Garden and LongHorn outperformed a softer casual-dining market, while…

DRI $24B

Investing 501 Dec 17

Takeaways From McDonald's Investor Day

McDonald’s investor day framed digital loyalty scale, delivery and AI-driven offer personalization as drivers of incremental restaurant…

MCD $173B

Investing 501 Dec 7

Does anyone remember when Alnylam went up 50 percent in a day on a phase three result

Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.

ALNY $31B

John Hempton's Newsletter Sep 12

Value Roundup

Talen’s post-bankruptcy nuclear assets, FREIT’s $22 Kushner bid and Calithera’s failed liquidation vote illustrate unusual small-cap…

TLN $17B

Exploring with Alluvial Capital Jul 5

Latest News

A Capital on X

George Noble on X

Calvin Blissett on X

A Capital on X

Myles on X

A Capital on X

Lee Roach on X

Convequity on X

Investor Letters

Recent recaps

Latest recap

Publications we follow

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 52 of 235

X accounts we follow

Investor letters we follow

Sectors